Talabostat - BioXcel Therapeutics

Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701; Talabostat mesilate; Talabostat mesylate

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 13 Nov 2017 BioXcel Therapeutics and Nektar Therapeutics agree to co-develop talabostat in combination with NKTR 214 (Combination therapy) in USA for Cancer
  • 03 Nov 2017 Phase-I clinical trials in Solid tumours in USA (PO) prior to 03/11/2017 (BioXcel pipeline November 2017)
  • 16 May 2017 BioXcel Therapeutics plans a phase Ib/II trial for Solid tumours (Combination therapy) in Q2 2017 (BioXcel website, Inveni website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top